Additionally, existing drugs approved for menopause care that inhibit GnRH pulsatility, such as fezolinetant (brand name VEOZAH, manufactured by Astellas Pharma US Inc.), could potentially be repurposed for improving dementia risk (175, 176). Here, GNRH1 is linked to dementia.